Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2014 / Jan / Gene Therapy Clinical Trials
Research & Innovations

Gene Therapy Clinical Trials

The EMA approved the first gene therapy agent in 2012 – for lipoprotein lipase deficiency. Might gene therapies for ophthalmic disease reach the wards any time soon?

By Irv Arons, Mark Hillen 1/21/2014 1 min read

Share

0114-501-main_img

No safety problems have been reported in any the trials conducted to date and some of the more advanced studies have reported improvements in vision. But questions remain. Will gene therapy deliver a permanent cure or something less? What diseases can it treat? All of the currently ongoing trials are for posterior segment diseases – can anything be done for anterior segment disorders? And what will it cost per patient? Alipogene tiparvovec treatment may cost as much as $1.6 million per patient (4) but the extent of its worldwide market numbers in the hundreds – this is whole orders of magnitude smaller than potential market size of the ophthalmic diseases currently under investigation. What’s interesting is that again, in general, Big Pharma aren’t funding the trials; it’s academic centers and biotech firms that are – and it’s likely that pharmaceutical companies will acquire or license the successful agents and market them; an expenditure they expect to recoup. Whatever the eventual costs are, it looks like we may see the first gene therapies for ophthalmic diseases within the next 5–10 years. If these interventions are successful, that’s something to celebrate.

0114-501-fig1
0114-501-fig2
0114-501-fig3
-114-501-fig4
0114-501-fig5
0114-501-fig6

References

  1. European Medicines Agency, “EPAR summary for the public. Glybera (alipogene tiparvovec)”, October 25th, 2012.
  2. Human Stem Cells Institute Press Release, “HSCI receives approval to market Neovasculgen – the first Russian gene-therapy drug for treatment of peripheral arterial disease”, December 7th, 2011.
  3. S Pearson, H Jia, K Kandachi, “China approves first gene therapy”, Nat Biotechnol., 22(1), 3-4 (2004).
  4. J Whalen, “Gene-Therapy Approval Marks Major Milestone”, Wall Street Journal, November 2nd, 2012.

About the Author(s)

Irv Arons

Irv Arons’ Journal is a well-read blog that reports on new drugs and devices for the treatment of retinal diseases, including age-related macular degeneration (AMD). Until his retirement, Irv was a consultant to the ophthalmic and medical laser industries, working for management consultants Arthur D. Little for 25 years and running his own company, Spectrum Consulting, for 11 years.

More Articles by Irv Arons

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

More Articles by Mark Hillen

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: